Naoko Takebe to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications Naoko Takebe has written about Antimetabolites, Antineoplastic.
Connection Strength
0.632
-
Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene. Cancer Gene Ther. 2002 Mar; 9(3):308-20.
Score: 0.194
-
Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Mol Ther. 2001 Jan; 3(1):88-96.
Score: 0.179
-
Drug delivery of oral anti-cancer fluoropyrimidine agents. Expert Opin Drug Deliv. 2017 12; 14(12):1355-1366.
Score: 0.138
-
Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther. 2001 Dec; 8(12):966-73.
Score: 0.048
-
Purine salvage rescue by xanthine-guanine phosphoribosyltransferase (XGPRT) potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene. Cancer Gene Ther. 1998 May-Jun; 5(3):144-9.
Score: 0.037
-
Co-expression of the herpes simplex virus thymidine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene. Gene Ther. 1997 Jun; 4(6):570-6.
Score: 0.035